SOLUBLE CELL ADHESION MOLECULES QUANTIFICATION IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: PROGNOSTIC IMPLICATIONS AND CLINICAL-BIOLOGICAL ASSOCIATIONS
- 1FMUSP, São Paulo, SP, Brazil
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and shows marked prognostic heterogeneity. Current risk stratification relies mainly on the International Prognostic Index (IPI), which does not incorporate relevant biological variables. Cell adhesion molecules (CAM) are involved in tumor proliferation, survival and dissemination, but their role in DLBCL remains poorly defined. We investigated plasma levels of soluble CAM (sICAM-1, sVCAM-1, sP-selectin and sE-cadherin) at diagnosis and their clinical and prognostic significance. Methods: This prospective longitudinal study included 87 newly diagnosed DLBCL patients treated at the University of São Paulo, Brazil, between April 2021 and January 2025. Immunosuppression-related DLBCL and patients previously exposed to corticosteroids, cytoreductive chemotherapy or radiotherapy were excluded. Plasma sCAM levels were measured by sandwich ELISA. Optimal cut-offs for overall survival (OS) and event-free survival (EFS) were determined using maximally selected rank statistics. Associations with clinical features, treatment response, relapse/progression and death were assessed using Wilcoxon, chi-square or Fisher’s exact tests. Results: Median age was 63 years, 53% were female, 64% had stage III/IV disease, 47% bulky disease ≥7 cm, 54% B-symptoms and 23% ECOG ≥2. All patients received R-CHOP-like therapy; overall response rate was 84% and complete response (CR) 80%. At a median follow-up of 1.09 years, 2-year OS and EFS were 76% and 74%, respectively. Among all sCAM, only sE-cadherin showed prognostic significance. The optimal OS cut-off was 126.55 ng/mL (p=0.034). Patients with sE-cadherin <126.55 ng/mL had superior 2-year OS compared with those with levels ≥126.55 ng/mL (92% vs 53%; p<0.001), and median OS was not reached versus 2.3 years, respectively. Higher sE-cadherin levels were observed in patients who died (145 vs 102 ng/mL; p=0.015), failed to achieve CR (135 vs 102 ng/mL; p=0.019), or developed progression/relapse (136 vs 101 ng/mL; p=0.016). Levels ≥126.55 ng/mL were also associated with B-symptoms (83% vs 33%; p<0.001), anemia (71% vs 29%; p<0.001), and IPI ≥3 (63% vs 39%; p=0.031). In multivariate analysis, baseline sE-cadherin ≥126.55 ng/mL independently predicted inferior OS (HR 3.51, 95% CI 1.01–11.21; p=0.034). sICAM-1, sVCAM-1 and sP-selectin showed no prognostic impact. Conclusion: This study identifies plasma sE-cadherin as a novel independent prognostic biomarker in newly diagnosed DLBCL. Elevated baseline levels were associated with adverse clinical features, lower response to R-CHOP, higher relapse/progression risk and inferior OS, supporting its potential role in risk stratification and as a candidate therapeutic target.
Related
- Transfer Learning-Based Quantification of Mitotic Activity and Its Prognostic and Molecular Associations in Lung Squamous Cell Carcinoma.
- Body mass index and overall survival in patients with gastric cancer: stage-specific associations and prognostic implications
- Deep learning–based quantification of muscle volume and attenuation and their associations with preinjury ambulatory status in patients with hip fractures
- A pathomics model for predicting lactate-related prognostic risk groups and their biological mechanisms in lung adenocarcinoma
- Molecular Fingerprinting Enables Mass Quantification and Semi-Quantitative Source Apportionment of Black Carbon in Biological Samples and Beyond
BibTeX
@article{silva2026soluble,
title = {{SOLUBLE CELL ADHESION MOLECULES QUANTIFICATION IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: PROGNOSTIC IMPLICATIONS AND CLINICAL-BIOLOGICAL ASSOCIATIONS}},
author = {Paola Carolina RABESQUINI MARCELINO DA SILVA and Igor CEREJO TAVARES DA SILVA DE ALMEIDA and Joaquim GASPARINI DOS SANTOS and Cadiele Oliana REICHERT and Hebert Fabrício CULLER and Renata DE OLIVEIRA COSTA and Débora LEVY and Vanderson ROCHA and Juliana PEREIRA and Luiz Alberto DE PADUA COVAS LAGE},
journal = {Hematology, Transfusion and Cell Therapy},
year = {2026},
month = oct,
doi = {10.1016/j.htct.2026.107828},
url = {https://doi.org/10.1016/j.htct.2026.107828},
note = {CC BY},
}
RIS
TY - JOUR
TI - SOLUBLE CELL ADHESION MOLECULES QUANTIFICATION IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: PROGNOSTIC IMPLICATIONS AND CLINICAL-BIOLOGICAL ASSOCIATIONS
AU - Paola Carolina RABESQUINI MARCELINO DA SILVA
AU - Igor CEREJO TAVARES DA SILVA DE ALMEIDA
AU - Joaquim GASPARINI DOS SANTOS
AU - Cadiele Oliana REICHERT
AU - Hebert Fabrício CULLER
AU - Renata DE OLIVEIRA COSTA
AU - Débora LEVY
AU - Vanderson ROCHA
AU - Juliana PEREIRA
AU - Luiz Alberto DE PADUA COVAS LAGE
PY - 2026
DA - 2026/10/23
JO - Hematology, Transfusion and Cell Therapy
DO - 10.1016/j.htct.2026.107828
UR - https://doi.org/10.1016/j.htct.2026.107828
AB - Background: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and shows marked prognostic heterogeneity. Current risk stratification relies mainly on the International Prognostic Index (IPI), which does not incorporate relevant biological variables. Cell adhesion molecules (CAM) are involved in tumor proliferation, survival and dissemination, but their role in DLBCL remains poorly defined. We investigated plasma levels of soluble CAM (sICAM-1, sVCAM-1, sP-selectin and sE-cadherin) at diagnosis and their clinical and prognostic significance. Methods: This prospective longitudinal study included 87 newly diagnosed DLBCL patients treated at the University of São Paulo, Brazil, between April 2021 and January 2025. Immunosuppression-related DLBCL and patients previously exposed to corticosteroids, cytoreductive chemotherapy or radiotherapy were excluded. Plasma sCAM levels were measured by sandwich ELISA. Optimal cut-offs for overall survival (OS) and event-free survival (EFS) were determined using maximally selected rank statistics. Associations with clinical features, treatment response, relapse/progression and death were assessed using Wilcoxon, chi-square or Fisher’s exact tests. Results: Median age was 63 years, 53% were female, 64% had stage III/IV disease, 47% bulky disease ≥7 cm, 54% B-symptoms and 23% ECOG ≥2. All patients received R-CHOP-like therapy; overall response rate was 84% and complete response (CR) 80%. At a median follow-up of 1.09 years, 2-year OS and EFS were 76% and 74%, respectively. Among all sCAM, only sE-cadherin showed prognostic significance. The optimal OS cut-off was 126.55 ng/mL (p=0.034). Patients with sE-cadherin <126.55 ng/mL had superior 2-year OS compared with those with levels ≥126.55 ng/mL (92% vs 53%; p<0.001), and median OS was not reached versus 2.3 years, respectively. Higher sE-cadherin levels were observed in patients who died (145 vs 102 ng/mL; p=0.015), failed to achieve CR (135 vs 102 ng/mL; p=0.019), or developed progression/relapse (136 vs 101 ng/mL; p=0.016). Levels ≥126.55 ng/mL were also associated with B-symptoms (83% vs 33%; p<0.001), anemia (71% vs 29%; p<0.001), and IPI ≥3 (63% vs 39%; p=0.031). In multivariate analysis, baseline sE-cadherin ≥126.55 ng/mL independently predicted inferior OS (HR 3.51, 95% CI 1.01–11.21; p=0.034). sICAM-1, sVCAM-1 and sP-selectin showed no prognostic impact. Conclusion: This study identifies plasma sE-cadherin as a novel independent prognostic biomarker in newly diagnosed DLBCL. Elevated baseline levels were associated with adverse clinical features, lower response to R-CHOP, higher relapse/progression risk and inferior OS, supporting its potential role in risk stratification and as a candidate therapeutic target.
SN - 2531-1379
SN - 2531-1387
ER -